Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > fda max

: 10 mg/d (adults)

or 20 mg/d

or No fixed maximum; titrated to TSH target

Use the filters below to narrow your results.

None (2) · Bisoprolol (1) · Cetirizine (1) · Levothyroxine (1) · Loratadine (1) · Montelukast (1) · Terazosin (1) · Thyroid (desiccated) (1) · Vardenafil (1)

Armour Thyroid, NP Thyroid, Nature-Throid, WP Thyroid (1) · Belsomra (1) · Claritin, Alavert, Tavist ND (1) · Hytrin (US brand discontinued); mostly generic (1) · Levitra, Staxyn (1) · Singulair (1) · Synthroid, Levoxyl, Tirosint, Unithroid, Euthyrox (1) · Trintellix (US), Brintellix (formerly) (1) · Zebeta (1) · Zyrtec, Zyrtec-D (1)

Beta Blocker (1) · Cardioselective (β1) (1) · Dual orexin receptor antagonist (DORA) (1) · Multimodal antidepressant: SERT inhibitor + 5HT1A agonist + 5HT1B partial agonist + 5HT3/5HT7 antagonist (1) · PDE5 Inhibitor (1) · the first approved (1) · [[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (1) · [[:Category:Antiasthmatic_agents|Antiasthmatic]] (1) · [[:Category:Antihistamines|Antihistamine]] (2) · [[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) · [[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (2) · [[:Category:Hormone_replacement|Hormone replacement]] (2) · [[:Category:Leukotriene_receptor_antagonists|Leukotriene receptor antagonist]] (1) · [[:Category:Thyroid_hormones|Thyroid hormone]] (2)

None (2) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) · Synthetic T4 (thyroxine); peripherally deiodinated to T3 (triiodothyronine), the active hormone. '"`UNIQ--vote-00000031-QINU`"' Narrow therapeutic index; brand-to-generic switches can shift TSH and require re-titration'"`UNIQ--ref-00000032-QINU`"'. (1) · '"`UNIQ--vote-00000032-QINU`"' Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic'"`UNIQ--ref-00000033-QINU`"'. (1) · '"`UNIQ--vote-00000391-QINU`"' Minimal CYP metabolism; mostly renally cleared unchanged. Cetirizine is the active racemate; levocetirizine is the active R-enantiomer marketed separately'"`UNIQ--ref-00000392-QINU`"'. (1) · '"`UNIQ--vote-0000061E-QINU`"' Less reliably anticholinergic than first-generation H1s; minimal antiemetic effect. Desloratadine (Clarinex) is the active enantiomer-of-metabolite version marketed as a Rx alternative. (1) · '"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)

1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) · 1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 10 mg PO once daily (1) · 10 mg PO once daily (5 mg in older adults or if sedation occurs) (1) · 10 mg PO once daily in the evening (adults); 4-5 mg in children (1) · 10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) · 10 mg ~1 h before sexual activity (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine (1)

1, 2, 5, 10 mg capsules and tablets (1) · 10 mg tablets; 4 mg, 5 mg chewables; 4 mg granules (1) · 10 mg tablets; 5 mg ODT and chewables; 1 mg/mL oral syrup; combo Claritin-D (with pseudoephedrine, behind-counter) (1) · 15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg) (1) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available (1) · 5 mg, 10 mg tablets; 5 mg, 10 mg chewables; 1 mg/mL oral syrup; OTC (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1) · 5 mg, 10 mg, 20 mg tablets (1) · 5, 10 mg tabs (1)

IV (1) · Oral (10)

1-3 hours (slower onset than cetirizine; symptom relief somewhat less) (1) · 1–2 h (1) · 30-60 minutes (1) · BP and symptomatic LUTS improvement within 1-2 weeks (1) · Bronchodilation within 1-2 hours; full controller effect 1-2 weeks (1) · TSH normalization 4-8 weeks (1) · TSH normalization 4-8 weeks; symptomatic improvement weeks to months (1) · Typical antidepressant 4-6 week onset (1) · ~30 min (2)

24 h (1) · 24 hours (4) · 4–5 h (1) · Daily dosing (1) · Steady-state at 4-6 weeks (2) · ~7-8 hours (1)

2.7-5.5 hours'"`UNIQ--ref-0000015E-QINU`"' (1) · 4–5 h (1) · 8-10 hours (longer in elderly and renal impairment)'"`UNIQ--ref-00000396-QINU`"' (1) · 9–12 h (1) · T4 ~7 days; T3 ~1 day'"`UNIQ--ref-00000036-QINU`"' (1) · ~12 hours (1) · ~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) · ~66 hours (1) · ~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"' (1) · ~8 hours (parent); ~28 hours (desloratadine, the active metabolite, marketed separately as Clarinex)'"`UNIQ--ref-00000621-QINU`"' (1)

40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) · >90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) · High (oral); not significantly affected by food'"`UNIQ--ref-00000397-QINU`"' (1) · High (oral; food prolongs absorption modestly)'"`UNIQ--ref-00000622-QINU`"' (1) · Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"' (1) · ~15% (extensive hepatic first-pass) (1) · ~64% (oral; not significantly affected by food)'"`UNIQ--ref-0000015F-QINU`"' (1) · ~75% (1) · ~82% (1) · ~90% (low first-pass) (1)

Category B (1) · Category C (1) · First-line in pregnancy; dose typically increased 25-30% due to estrogen-driven rise in TBG and fetal demand. Lactation safe at physiologic doses.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; pregnancy registries do not show increased major malformation risk.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; widely used. Levocetirizine (the R-enantiomer) is an alternative with similar safety.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; widely used. Loratadine and cetirizine are the most-recommended 2nd-gen H1s in pregnancy and lactation.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; avoid (1) · Limited data; weigh benefits/risks (1) · Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied[[[Pharmacopedia:Citation needed|citation needed]]] (1)

OTC in US (2) · Rx (1) · Rx, Schedule IV (US) (1) · Rx-only in US (2) · [[USLegal:Prescription only|Rx-only]] in US (3) · [[USLegal:Prescription only|Rx-only]] in US. '''FDA Boxed Warning (2020):''' neuropsychiatric events including agitation, depression, sleep disturbance, and suicidal thoughts; benefit-risk should be reassessed regularly'"`UNIQ--ref-00000160-QINU`"'. (1)

Showing below up to 10 results in range #1 to #10.